

FORM C

Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 1992 Regulation 13 (6)

Page 1 of 1

Regulation 13(6) – Details of acquisition of 5% or more shares in a listed company

Name & address of shareholder with telephone number	Shareholding prior to acquisition	No. and percentage of shares / voting rights acquired / sold	Receipt of allotment / advice. acquisition of shares / sale of shares (specify)	Date of intimation to Company	Mode of acquisition (market purchase/ public/ rights / preferential offer etc.)	No. and percentage of shares / voting rights post acquisition / sale	Trading member through whom the trade was executed with SEBI Registration No. of the TM	Exchange on which the trade was executed	quantity	Value
Arisaig Partners (Asia) Pte Limited (FII) C/o Arisaig India Fund Limited ("AIF") IFS Court, Twenty Eight, Cybercity, Ebene, Mauritius PAN : AACCA6666M Tel: 65 6532 3378 Fax: 65 6532 6618 e-mail: cheeseng@arisaig.com.sg	2,106,101 equity shares (5.01 %)	6,897 equity shares (0.016 %)	Sale of Shares	Faxed letter dated 13 th June 2013	Market Sale	2,099,204 equity shares (4.99 %)	NSE INB 230826436 (CLSA India Limited)	NSE	6,897 equity shares	INR 40,265,288
Total	2,106,101 Equity shares amounting to 5.01 % of the paid up equity share capital					2,099,204 Equity shares amounting to 4.99 % of the paid up equity share capital				

Date : 14.06.2013



For GlaxoSmithKline
Consumer Healthcare Limited

Surinder Kumar

Surinder Kumar
Executive Vice President – Legal & Company Secretary